phrykt

CRISPR Therapeutics AG (CRSP): who owns it and who trades it

As of Nov 16, 2026, CRSP insiders reported 30 open-market sales worth $17.9M and no purchases in the last 12 months, with 5% of the sale value made under pre-set 10b5-1 plans. The largest seller was Samarth Kulkarni (CEO), with $9.6M. 5 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Crispr Therapeutics

From the latest filings

Overall: more selling than buying. Insiders and famous investors mostly sold. Funds was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns CRSP

519 funds and institutions reported CRSP shares worth $4.3B at the end of Q2 2026, about 86% of the company. The largest holder is ARK Investment Management LLC with 9.8%.

Funds and institutions (13F) 86%Everyone else 14%

10 largest owners, by share of the company

ARK Investment Management LLC9.8%
BlackRock, Inc.8.7%
Orbis Allan Gray Ltd5.6%
California State Teachers Retirement System5.6%
Capital World Investors4.9%
State Street Corp4.5%
GSK plc3.3%
Geode Capital Management, LLC2.6%
T. Rowe Price Investment Management, Inc.2.1%
SR One Capital Management, LP2.1%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
ARK Investment Management LLC9.46M9.81%$516M-16%
BlackRock, Inc.8.35M8.66%$455M+9%
Orbis Allan Gray Ltd5.45M5.65%$297M-11%
California State Teachers Retirement System5.35M5.55%$98.2M+5189%
Capital World Investors4.75M4.92%$259M+1%
State Street Corp4.32M4.48%$236M+9%
GSK plc3.22M3.34%$176MNo change
Geode Capital Management, LLC2.51M2.60%$137M+6%
T. Rowe Price Investment Management, Inc.2.05M2.13%$112M-30%
SR One Capital Management, LP2.04M2.11%$111MNo change
Two Sigma Investments, LP1.99M2.06%$108M+34%
FMR LLC (Fidelity)1.91M1.98%$104M-2%
Sumitomo Mitsui Trust Group, Inc.1.72M1.78%$93.8M-7%
Amova Asset Management Americas, Inc.1.72M1.78%$93.8M-7%
EcoR1 Capital, LLC1.39M1.44%$75.8MNo change
UBS Group AG1.32M1.37%$71.9M-25%
Capital International Investors1.27M1.32%$69.2M+7%
Vanguard Capital Management LLC1.18M1.23%$64.5M+3%
Bank of America Corp1.16M1.20%$63M+17%
NEA Management Company, LLC1.06M1.10%$57.7MNo change

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, CRSP insiders reported $0 of open-market purchases and $17.9M of sales. 5% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$17.9M
30 trades, 6 people
Sales under a 10b5-1 plan
5%
Share of sale value
Latest trade
Oct 19, 2026
Filed Oct 20, 2026

Purchases and sales by month

$9.1M$9.1MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Oct 19, 2026Samarth KulkarniCEOSale47,837$49.78$2.4MForm 4
Oct 14, 2026Simeon GeorgeDirectorSale plan14,514$49.63$720KForm 4
Oct 14, 2026Samarth KulkarniCEOSale4,098$49.26$202KForm 4
Oct 14, 2026James R. KasingerGeneral Counsel and SecrSale1,040$49.26$51.2KForm 4
Oct 6, 2026James R. KasingerGeneral Counsel and SecrSale plan1,990$60.04$119KForm 4
Sep 22, 2026James R. KasingerGeneral Counsel and SecrSale10,400$60.24$626KForm 4
Sep 17, 2026Ali BehbahaniDirectorSale13,679$57.09$781KForm 4
May 29, 2026Naimish PatelChief Medical OfficerSale3,786$55.62$211KForm 4
Mar 23, 2026James R. KasingerGeneral Counsel and SecrSale3,182$46.78$149KForm 4
Mar 23, 2026Samarth KulkarniCEOSale10,020$46.78$469KForm 4
Mar 23, 2026Raju PrasadCFOSale3,708$46.78$173KForm 4
Mar 16, 2026Naimish PatelChief Medical OfficerSale3,150$48.26$152KForm 4
Mar 16, 2026Raju PrasadCFOSale5,848$48.26$282KForm 4
Mar 16, 2026Raju PrasadCFOSale4,021$48.26$194KForm 4
Mar 16, 2026James R. KasingerGeneral Counsel and SecrSale3,450$48.26$166KForm 4
Mar 16, 2026Samarth KulkarniCEOSale10,349$48.26$499KForm 4
Mar 11, 2026James R. KasingerGeneral Counsel and SecrSale2,800$52.80$148KForm 4
Mar 11, 2026Samarth KulkarniCEOSale9,798$52.80$517KForm 4
Feb 19, 2026Samarth KulkarniCEOSale6,967$52.58$366KForm 4
Feb 19, 2026James R. KasingerGeneral Counsel and SecrSale2,112$52.58$111KForm 4
Jan 22, 2026Raju PrasadCFOSale34,972$60.19$2.1MForm 4
Jan 22, 2026Samarth KulkarniCEOSale60,000$60.23$3.6MForm 4
Jan 20, 2026Samarth KulkarniCEOSale21,433$51.61$1.1MForm 4
Jan 20, 2026Samarth KulkarniCEOSale8,567$52.10$446KForm 4
Jan 6, 2026Raju PrasadCFOSale5,763$60.21$347KForm 4
Jan 6, 2026Raju PrasadCFOSale5,004$60.00$300KForm 4
Jan 6, 2026Raju PrasadCFOSale18,933$60.18$1.1MForm 4
Dec 22, 2025Raju PrasadCFOSale3,528$55.10$194KForm 4
Dec 22, 2025Raju PrasadCFOSale1,000$56.89$56.9KForm 4
Dec 22, 2025Raju PrasadCFOSale5,472$56.33$308KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Samarth KulkarniChief Executive Officer, Director–$9.6MOct 19, 2026
Raju PrasadChief Financial Officer–$5.1MMar 23, 2026
James R. KasingerGeneral Counsel and Secretary–$1.4MOct 14, 2026
Ali BehbahaniDirector–$781KSep 17, 2026
Simeon GeorgeDirector–$720KOct 14, 2026
Naimish PatelChief Medical Officer–$363KMay 29, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

CRSP short interest

High short interest. 17.7% of CRSP shares are sold short: about 1 share in 6. Over the last 12 reports the number of shares short went down 37%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 17.19M CRSP shares were sold short, 17.7% of the shares outstanding, up 4.5% from the report before. At the average daily volume of 1.31M shares, buying them all back would take about 13.1 trading days (days to cover).

Shares short, % of all shares

17.7%May 15Oct 3030.0%

Days to cover

13.1May 15Oct 3017.6

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 202617.19M17.72%+5%1.31M13.1
Oct 15, 202616.44M17.00%-12%1.61M10.2
Sep 30, 202618.68M19.32%-2%1.95M9.6
Sep 15, 202619.07M19.72%+2%1.15M16.5
Aug 31, 202618.77M19.41%+0%1.75M10.7
Aug 14, 202618.74M19.39%-0%1.20M15.6
Jul 31, 202618.82M19.46%-5%1.63M11.5
Jul 15, 202619.81M20.54%-3%1.71M11.6
Jun 30, 202620.40M21.15%-23%1.75M11.7
Jun 15, 202626.57M27.55%+23%1.63M16.4
May 29, 202621.67M22.47%-21%1.76M12.3
May 15, 202627.29M28.30%+21%1.65M16.5

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Crispr Therapeutics company events

Crispr Therapeutics filed 9 reports on Form 8-K in the last 12 months, 2 of them about an important change (leadership). The latest was on Nov 2, 2026.

  1. Nov 2, 2026ResultsReleased financial results. Filing
  2. Oct 19, 2026LeadershipCRISPR Therapeutics AG announced the promotion of Andrew J. Silver, currently the Company’s SVP, Finance, to be the Company’s Chief Financial Officer effective immediately. Filing
  3. Aug 3, 2026ResultsReleased financial results. Filing
  4. Jun 4, 2026LeadershipAt the 2026 Annual General Meeting of Shareholders, the shareholders of CRISPR Therapeutics AG approved the CRISPR Therapeutics AG 2026 Stock Option and Incentive Plan. Filing
  5. May 4, 2026ResultsReleased financial results. Filing
  6. Mar 16, 2026AgreementCRISPR Therapeutics AG completed its previously announced private offering of $600.0 million of its Convertible Senior Notes due 2031, including the exercise in full of the initial purchasers’ option to purchase up to an additional $50.0 million principal amount of Notes. Filing
  7. Mar 11, 2026AnnouncementCRISPR Therapeutics AG issued a press release announcing that it had commenced a private offering, subject to market conditions and other factors, of $350.0 million of convertible senior notes due 2031 to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under… Filing
  8. Feb 12, 2026ResultsReleased financial results. Filing
  9. Jan 12, 2026AnnouncementCRISPR Therapeutics AG issued a press release highlighting, among other things, selected updates related to its wholly-owned cardiovascular, autoimmune, immuno-oncology and regenerative medicine programs: • The Company continues to advance a diversified portfolio of in vivo gene editing programs… Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Crispr Therapeutics financials

Famous investors that hold CRSP

5 of the 50 well-known investors we track reported holding CRSP in their latest 13F filing. The largest position is Cathie Wood's, worth $556M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Cathie Wood · ARK Investment ManagementQ3 202610.06M$556M3.2%+6%
Israel Englander · Millennium ManagementQ3 202691,630$5.1M0.0%-76%
Ken Fisher · Fisher Asset ManagementQ3 202667,302$3.7M0.0%-14%
Paul Tudor Jones · Tudor Investment CorpQ3 202652,520$2.9M0.0%+24%
Ken Griffin · Citadel AdvisorsQ3 20264,680$259K0.0%-99%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 6 filings named CRSP in the last 120 days.

FiledHolderFormStake
Nov 16, 2026ORBIS INVESTMENT MANAGEMENT LTD13G/A4.7%
Nov 16, 2026ORBIS INVESTMENT MANAGEMENT LTD13G/A4.7%
Nov 13, 2026ARK Investment Management LLC13G/A10.4%
Nov 13, 2026ARK Investment Management LLC13G/A10.4%
Nov 10, 2026STATE STREET CORPORATION13G5.2%
Nov 10, 2026STATE STREET CORPORATION13G5.2%

Questions about CRISPR Therapeutics AG (CRSP) stock

Who owns the most CRSP stock?

The largest reported owner of CRISPR Therapeutics AG (CRSP) is ARK Investment Management LLC, with 9.8% of the company. In total, 519 funds and institutions reported holding CRSP at the end of Q2 2026, together about 86% of the shares. See the largest owners.

Are CRSP insiders buying or selling?

In the last 12 months, CRSP insiders reported no open-market purchases and 30 sales worth $17.9M. The latest trade was on Oct 19, 2026. See every trade.

What is the short interest in CRSP?

As of Oct 30, 2026, 17.19M CRSP shares were sold short, 17.7% of the shares outstanding, up 4.5% from the report before. At the average daily volume of 1.31M shares, buying them all back would take about 13.1 trading days (days to cover). See the history.

Which famous investors hold CRSP?

5 of the 50 well-known investors we track reported CRSP in their latest 13F filing, including Cathie Wood, Israel Englander, Ken Fisher. The largest position is worth $556M. See all holders.

Executive pay

Crispr Therapeutics's chief executive was paid a total of $7.7M for the year ended Dec 31, 2025, down 77% from $33.2M the year before. In the last 12 months, Crispr Therapeutics's executives and directors bought $49.7K of stock on the open market and sold $17.9M.

Chief executive, total pay$7.7MYear ended Dec 31, 2025. Salary, bonus and the value of stock and option awards when granted.
Pay "actually paid"$22MThe same year, with stock awards valued at what they were worth as they vested or at year end.
Other top executives, average$3.6MThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.